Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 30Prostatic Neoplasms 18Lung Neoplasms 17Breast Neoplasms 17Glioblastoma 16Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 14Pancreatic Neoplasms 13Multiple Myeloma 12Glioma 12Brain Neoplasms 11Carcinoma, Renal Cell 10Squamous Cell Carcinoma of Head and Neck 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Follicular 9Astrocytoma 9Neoplasms 8Melanoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Lymphoma, Non-Hodgkin 7Cholangiocarcinoma 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 6Gliosarcoma 6Central Nervous System Neoplasms 6Carcinoma 6

Interventions

pomalidomide 1Vincristine 1Specimen Handling 1Rituximab 1Prednisone 1Magnetic Resonance Spectroscopy 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Plasmablastic Lymphoma × Magnetic Resonance Spectroscopy × Clear all
NCT07332507 2026-05-13

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
Lymphoid

Plasmablastic Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡